FDA Approves Merck’s Lipfendra, First Oral Cholesterol Pill

The U.S. Food and Drug Administration has approved Merck’s Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor capable of reducing LDL cholesterol by up to 59% — far exceeding what traditional statins can achieve alone. Announced on July 16, 2026, the approval marks a major breakthrough in cardiovascular medicine, offering millions of patients a powerful new tool in the fight against heart disease, the leading cause of death in the United States.

A New Class of Cholesterol Medication

Lipfendra is a novel macrocyclic peptide that works by blocking the PCSK9 protein, which plays a vital role in regulating cholesterol levels. Unlike injectable PCSK9 inhibitors such as Amgen’s Repatha and Regeneron and Sanofi’s Praluent — which cost $500 to $600 or more per month — Lipfendra is administered as a convenient 20 mg daily pill with a list price of $315 for a 30-day supply, or about $10.50 per day.

According to Merck, the drug is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), a genetic condition that causes dangerously high cholesterol levels.

Clinical Trial Results

The FDA’s decision was based on two pivotal Phase 3 trials from Merck’s CORALreef clinical program. In the CORALreef Lipids trial, Lipfendra reduced LDL-C by 56% compared to placebo at week 24, with patients on the drug experiencing a 57% reduction from baseline while placebo patients saw a 3% increase. In the CORALreef HeFH trial, the drug achieved a 59% reduction compared to placebo.

Secondary endpoints were also significant: Lipfendra reduced non-HDL-C by 54% and apolipoprotein B (ApoB) by 50% in the CORALreef Lipids trial, with similar results in the HeFH study.

Dr. Ann Marie Navar, lead author of the CORALreef Lipids study and associate professor of medicine at UT Southwestern Medical Center, highlighted the significance of the results. “In two Phase 3 trials, LIPFENDRA led to impressive reductions in LDL-C,” she said in a Merck press release. “Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering.”

Safety and Tolerability

A key advantage of Lipfendra is its favorable side-effect profile. In the CORALreef Lipids trial, adverse reactions were similar between the drug and placebo groups, with no muscle aches — a common complaint among statin users. In the HeFH trial, the most common side effects occurring at higher rates than placebo were dizziness (9% vs. 4%) and diarrhea (7% vs. 2%).

Dr. Paja Banka, associate vice-president for global clinical development at Merck, told The Guardian that the drug’s side effects “were like the placebo.” She noted that approximately 70% of patients are not reaching their LDL cholesterol goals with current treatments.

Why This Matters

Heart disease remains the leading cause of death in the U.S., and approximately one in four American adults has high LDL cholesterol, according to the American Heart Association. Statins have been the cornerstone of cholesterol treatment for decades, but many patients either cannot tolerate them or fail to reach recommended LDL targets.

New guidelines issued in March 2026 by the American College of Cardiology and the American Heart Association recommend increasingly aggressive LDL-C goals: below 100 mg/dL for borderline or intermediate risk, below 70 mg/dL for high risk, and below 55 mg/dL for those at very high risk with established atherosclerotic cardiovascular disease (ASCVD).

Katherine Wilemon, CEO of the Family Heart Foundation, welcomed the approval. “One of the greatest opportunities to help manage the risk of ASCVD lies in the timely identification and appropriate treatment of risk factors, such as LDL-C,” she said. “We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering.”

Market and Strategic Implications

Merck’s stock rose 3.5% on the news, as CNBC reported. The approval comes at a critical time for the pharmaceutical giant: its blockbuster cancer drug Keytruda is set to lose key patent protections starting in 2028, and Lipfendra helps diversify Merck’s portfolio ahead of that patent cliff.

Analysts project near-term sales could surpass $350 million in 2027, with long-term potential reaching $5 billion annually. Scotiabank analyst Louise Chen previously projected “peak sales potential of tens of billions of dollars.”

What’s Next

Lipfendra is expected to be available in pharmacies within a few weeks. The drug was a recipient of the FDA commissioner’s National Priority Voucher program, which accelerated its review.

An ongoing cardiovascular outcomes trial, CORALreef Outcomes (NCT06008756), has completed enrollment with over 14,500 participants and will determine whether the dramatic LDL reductions translate into fewer heart attacks, strokes, and cardiovascular deaths. The broader CORALreef program evaluates over 19,000 participants across multiple studies.

For now, the approval represents a paradigm shift in cholesterol management — offering patients, for the first time, a powerful oral alternative that can achieve the kind of LDL reductions previously only possible with expensive injections.